{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"54.0","value":"55.9"},{"groupId":"OG001","spread":"51.6","value":"52.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"493"},{"groupId":"OG001","value":"494"}],"units":"Participants"}],"title":"Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"87.8","value":"116.6"},{"groupId":"OG001","spread":"86.9","value":"106.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"410"},{"groupId":"OG001","value":"409"}],"units":"Participants"}],"title":"Day 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"137.4","value":"197.9"},{"groupId":"OG001","spread":"128.5","value":"158.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"269"},{"groupId":"OG001","value":"284"}],"units":"Participants"}],"title":"Day 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"156.0","value":"229.9"},{"groupId":"OG001","spread":"146.4","value":"145.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"199"}],"units":"Participants"}],"title":"Day 11"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"158.8","value":"175.9"},{"groupId":"OG001","spread":"134.9","value":"111.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"252"},{"groupId":"OG001","value":"267"}],"units":"Participants"}],"title":"Day 15"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"95.8","value":"16.5"},{"groupId":"OG001","spread":"107.9","value":"36.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"260"},{"groupId":"OG001","value":"254"}],"units":"Participants"}],"title":"Day 29"}],"denoms":[{"counts":[{"groupId":"OG000","value":"493"},{"groupId":"OG001","value":"494"}],"units":"Participants"}],"description":"Blood to evaluate platelets was collected at Days 1, 3, 5, 8, and 11 while participants were inpatient, and at Days 15 and 29, with the Day 1 assessment serving as baseline. Participants who had been discharged had blood collected if infection control measures allowed for in-person visits after discharge.","dispersionType":"Standard Deviation","groups":[{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG000","title":"Remdesivir Plus Baricitinib"},{"description":"200 mg of Remdesivir administered intravenously on Day 1, followed by a 100 mg once-daily maintenance dose of Remdesivir while hospitalized for up to a 10-day total course and 4 mg (2 tablets of 2 mg) of Baricitinib Placebo administered orally daily for the duration of the hospitalization up to a 14-day total course.","id":"OG001","title":"Remdesivir Plus Placebo"}],"paramType":"MEAN","populationDescription":"The safety population includes all treated participants with available data at baseline and the post baseline assessment point, analyzed as treated.","reportingStatus":"POSTED","timeFrame":"Days 1, 3, 5, 8, 11, 15 and 29","title":"Change From Baseline in Platelets","type":"SECONDARY","unitOfMeasure":"10^9 cells/liter"}